Ajinomoto Bio-Pharma Services, a US-based provider of biopharmaceutical contract development and manufacturing services, announced on Tuesday that it has been recognised with three CDMO Leadership Awards.
The company has received the honour in the categories Capabilities, Compatibility, and Expertise in both the Overall and Big Pharma respondent groups.
These awards are conferred by Life Science Leader magazine and Industry Standard Research. Seventy-two contract manufacturers were evaluated by 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration